A drug long prescribed for a rare lung condition has revealed an unexpected capacity to interrupt one of cancer's most lethal maneuvers — the ability to spread. Researchers at the University of São Paulo found that ambrisentan, already approved for pulmonary hypertension, significantly reduced tumor migration and extended survival across multiple cancer types in laboratory and animal studies. The discovery invites a familiar question in medicine: whether a molecule shaped for one disease might quietly hold answers for another, and whether the path from animal model to human benefit will prove
News-Medical.net
· Dec 15, 2020
· health
· 2 min de leitura
High
Apuração: Caracterizado
Pulmonary hypertension drug shows promise in blocking cancer metastasis
◉
Health & Medicine
7994 artigos relacionados
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% correspondência
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% correspondência
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Medical research on cancer drug repurposing has no direct geopolitical implications; this is a scientific advancement with potential healthcare benefits across nations.
Escalation Risk
low
Confidence
HIGH
No shifts in international power, alliances, or influence. This is biomedical research with global collaborative potential (Brazil-Germany-UAE partnership demonstrates open scientific cooperation).
Lente Econômica
📈
Pulmonary hypertension drug ambrisentan shows 47% reduction in cancer metastasis in animal trials, potentially opening new oncology treatment pathway and creating pharmaceutical repurposing opportunity.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Healthcare/Oncology
Medical Devices and Diagnostics
Patients with advanced cancers could gain access to a new treatment option with potentially fewer side effects than traditional chemotherapy if clinical trials succeed. However, benefits remain speculative until human trials demonstrate efficacy and safety.
FDA may expedite clinical trial pathways for drug repurposing given existing safety data from pulmonary hypertension use. Patent and exclusivity considerations for off-label use could emerge. Healthcare systems may need to evaluate cost-effectiveness of combination therapies.